Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Natera (NTRA) yesterday and set a price target of $30. The company’s shares closed on Friday at $21.70.
According to TipRanks.com, Massaro is a top 100 analyst with an average return of 18.4% and a 62.5% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Natera with a $24.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29.62 and a one-year low of $11.08. Currently, Natera has an average volume of 696.2K.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing.
